These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26105699)

  • 1. Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
    Brown MC; Gromeier M
    Discov Med; 2015 May; 19(106):359-65. PubMed ID: 26105699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
    Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK
    Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Poliovirus for Cancer Immunotherapy.
    Gromeier M; Nair SK
    Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
    Walton RW; Brown MC; Sacco MT; Gromeier M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic polio virotherapy of cancer.
    Brown MC; Dobrikova EY; Dobrikov MI; Walton RW; Gemberling SL; Nair SK; Desjardins A; Sampson JH; Friedman HS; Friedman AH; Tyler DS; Bigner DD; Gromeier M
    Cancer; 2014 Nov; 120(21):3277-86. PubMed ID: 24939611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
    Brown MC; Gromeier M
    Curr Opin Virol; 2015 Aug; 13():81-5. PubMed ID: 26083317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From virotherapy to oncolytic immunotherapy: where are we now?
    Coffin RS
    Curr Opin Virol; 2015 Aug; 13():93-100. PubMed ID: 26121656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
    Alvarez-Breckenridge CA; Choi BD; Suryadevara CM; Chiocca EA
    Curr Opin Virol; 2015 Aug; 13():25-32. PubMed ID: 25846988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viruses for cancer immunotherapy.
    Hemminki O; Dos Santos JM; Hemminki A
    J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo.
    Toyoda H; Wimmer E; Cello J
    Int J Oncol; 2011 Jan; 38(1):81-7. PubMed ID: 21109928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent Antitumor T-Cell Memory Is Generated by Curative Viral Oncolytic Immunotherapy But Not Curative Chemotherapy.
    Gao Y; Bergman I
    Anticancer Res; 2018 Dec; 38(12):6621-6629. PubMed ID: 30504370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
    Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
    J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.
    Cassady KA; Haworth KB; Jackson J; Markert JM; Cripe TP
    Viruses; 2016 Feb; 8(2):. PubMed ID: 26861381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.